Edition:
United States

Mitsubishi Tanabe Pharma Corp (4508.T)

4508.T on Tokyo Stock Exchange

2,338JPY
30 Mar 2017
Change (% chg)

-- (--)
Prev Close
¥2,338
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
913,440
52-wk High
¥2,384
52-wk Low
¥1,729

Latest Key Developments (Source: Significant Developments)

Mitsubishi Tanabe Pharma enters into Invossa licensing agreement with Kolon Life Science
Tuesday, 1 Nov 2016 01:22am EDT 

Mitsubishi Tanabe Pharma Corp <4508.T> : Says co and Kolon Life Science have concluded a licensing agreement for Invossa, a cell therapy product for improvement of symptoms of knee osteoarthritis .According to the agreement co will acquire exclusive development and commercialization rights for Invossa in Japan.  Full Article

FDA accepts Mitsubishi Tanabe Pharma's NDA filing for Edaravone to treat ALS
Tuesday, 30 Aug 2016 08:45am EDT 

Mitsubishi Tanabe Pharma <4508.T> : FDA accepts Mitsubishi Tanabe Pharma's NDA filing for Edaravone to treat ALS . FDA accepts Mitsubishi Tanabe Pharma's NDA filing for Edaravone to treat ALS .Says if approved, medicine will be commercialized, under brand name Radicava, through newly formed Mt Pharma America, Inc.  Full Article

R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook
Monday, 14 Mar 2016 02:00am EDT 

Mitsubishi Tanabe Pharma Corp:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+".Rating outlook stable.  Full Article

Mitsubishi Tanabe Pharma announces result of early-retirement program
Wednesday, 3 Feb 2016 02:00am EST 

Mitsubishi Tanabe Pharma Corp:Says 634 employees took up the offer of the early-retirement program announced on Oct. 30, 2015.Effective date of retirement is March 31.  Full Article

Mitsubishi Tanabe Pharma to offer early-retirement program
Friday, 30 Oct 2015 01:00am EDT 

Mitsubishi Tanabe Pharma Corp:To offer an early-retirement program to employees, who are above 45 years old as of April 1, 2016.Offering period from Dec. 1 to Dec. 25.Says the employees who take up the offer will retire on March 31, 2016.The company will provide retirement payment and outplacement support to the retiring employees.  Full Article

Mitsubishi Tanabe Pharma signs collaboration agreement with U.S-based company
Thursday, 1 Oct 2015 07:00pm EDT 

Mitsubishi Tanabe Pharma Corp:Says signed collaboration agreement with U.S-based company on Sep. 29.The U.S-based company to grant the company the exclusive development and distribution rights on an anti-NGF (Nerve Growth Factor) antibody (development code REGN475), in Asia (exclude Japan, Korea and China).  Full Article

Mitsubishi Tanabe Pharma raises consolidated mid-year and full-year outlook for FY 2016
Wednesday, 30 Sep 2015 02:00am EDT 

Mitsubishi Tanabe Pharma Corp:Says the company increased the consolidated mid-year outlook for revenue to 200,000 mln yen from 191,500 mln yen, for the fiscal year ending March 31, 2016.Operating profit forecast increased to 38,500 mln yen from 28,000 mln yen.Ordinary profit forecast increased to 38,000 mln yen from 28,000 mln yen.Net profit forecast increased to 25,500 mln yen from 19,000 mln yen.Earnings per share increased to 45.46 yen from 33.87 yen.Says the company increased the consolidated full-year outlook for revenue to 418,000 mln yen from 396,000 mln yen, for the fiscal year ending March 31, 2016.Operating profit forecast increased to 82,000 mln yen from 67,500 mln yen.Ordinary profit forecast increased to 81,000 mln yen from 67,000 mln yen.Net profit forecast increased to 46,000 mln yen from 40,500 mln yen.Earnings per share increased to 82 yen from 72.19 yen.Comments the improvement in domestic ethical pharmaceuticals business, and increased revenue of lump sum are the main reasons for the forecast.  Full Article

Mitsubishi Tanabe Pharma concludes patent, know-how transfer agreement with Dezima Pharma and Amgen
Wednesday, 16 Sep 2015 07:00pm EDT 

Mitsubishi Tanabe Pharma Corp:Concluded a patent, know-how transfer agreements for TA-8995 with Dezima Pharma B.V.(the licensee) and Amgen, Inc. (acquirer).The company will provide TA-8995 patents and rights to Amgen, worldwide, except for Japan and certain parts of Asia, where the company has retained the exclusive rights.Says the transaction will include a lump-sum payment of US $300 mln and milestone payments, and the company will receive from Dezima a portion from those payments over time.  Full Article

Mitsubishi Tanabe Pharma concludes license agreement with Bioqen
Wednesday, 9 Sep 2015 03:00am EDT 

Mitsubishi Tanabe Pharma Corp:Says the company has concluded a license agreement with Bioqen on MT-1303, a therapeutic agent for autoimmune diseases, discovered and development by the company.Says Bioqen is granted to the exclusive right to develop and market this drug globally except in Japan and in Asia.Says from Bioqen, the company has received an upfront payment of $60 mln, and may receive up to $484 mln as well as to receive royalties according to the sales volume after the Bioqen's marketing product.  Full Article

Mitsubishi Tanabe Pharma to issue year-end dividend for FY 2015
Friday, 8 May 2015 03:00am EDT 

Mitsubishi Tanabe Pharma Corp:To issue a year-end dividend of 22 yen per share to all the shareholders of record as of March 31, for FY ended March 2015.Payment date June 22.Says latest dividend forecast was 20 yen per share.  Full Article

More From Around the Web

BRIEF-Mitsubishi Tanabe Pharma to sell drug sales unit to Nipro after company division

* Says the co will transfer generic drug business and part of long-listed drugs business to its wholly owned unit, an Osaka-based drug sales firm, via company division